<p>This is a summary of the European public assessment report (EPAR) for Votrient. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Votrient.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p><strong>Renal-cell carcinoma (RCC)</strong></p> <p>Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.</p> <p><strong>Soft-tissue sarcoma (STS)</strong></p> <p>Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.</p> <p>Efficacy and safety have only been established in certain STS histological tumour subtypes.</p></div>
Therapeutic Area (MeSH)
ATC Code
L01XE11
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pazopanib | N/A | pazopanib |
EMA Name
Votrient
Medicine Name
Votrient
Aliases
N/ANo risk management plan link.
